Podoplanin is a potential marker for the diagnosis of ependymoma: A comparative study with epithelial membrane antigen (EMA)

Clinical Neuropathology

Volumn 28, Issue 5, 2009, Pages 373-378

  Ishizawa, K ^a   Komori, T ^b   Shimada, S ^a   Hirose, T ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Epithelial membrane antigen (EMA); Immunohistochemistry; Podoplanin ependymoma

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN ANTIBODY; PODOPLANIN; PODOPLANIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MUCIN 1; PDPN PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; EPENDYMOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE STRUCTURE; CHEMISTRY; IMMUNOLOGY; MICROPHOTOGRAPHY; PATHOLOGY;

EPENDYMOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MUCIN-1; PHOTOMICROGRAPHY;

EID: 70350059104     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.2379/NPX09169     Document Type: Article

References (21)

1. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D. Podoplanin, novel 43-kdmembrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997; 151: 1141-1152.
2. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999; 154: 385-394.
3. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005; 18: 105-110.
4. Figarella-Branger D, Gambarelli D, Dollo C, Devictor B, Perez-Castillo AM, Genitori L, Lena G, Choux M, Pellissier JF. Infratentorial ependymomas of childhood. Correlation between histological features, immunohistological phenotype, silver nucleolar organizer region staining values and post-operative survival in 16 cases. Acta Neuropathol. 1991; 82: 208-216.
5. Hasselblatt M, Paulus W. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. Acta Neuropathol. 2003; 106: 385-388.
6. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002; 15: 434-440.
7. Kahn HJ, Marks A. Anew monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002; 82: 1255-1257.
8. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun. 2006; 349: 1301-1307.
9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Chapter 3 Ependymall tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumors of the central nervous system, 4th edn.Lyon: IARCPress; 2007. pp. 69-80.
10. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer. 1999; 80: 569-578.
11. McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng HK. Anaplastic ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumours of the central nervous system, 4th edn. Lyon: IARC; 2007a. pp. 79-80.
12. McLendon RE,Wiestler OD, Kros JM, Korshunov A, Ng HK. Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumours of the central nervous system, 4th edn. Lyon: IARC; 2007b. pp. 74-78.
13. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, Matsutani M. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. 2006a; 111: 563-568.
14. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006b; 111: 483-488.
15. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M, Yamasaki M. D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol. 2006; 19: 974-985.
16. Roy S, Chu A, Trojanowski JQ, Zhang PJ. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol. 2005; 109: 497-502.
17. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005; 166: 913-921.
18. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006; 448: 493-499.
19. Uematsu Y, Rojas-Corona RR, Llena JF, Hirano A. Distribution of epithelial membrane antigen in normal and neoplastic human ependyma. Acta Neuropathol. 1989; 78: 325-328.
20. Vege KD, Giannini C, Scheithauer BW. The immunophenotype of ependymomas. Appl Immunohistochem Mol Morphol. 2000; 8: 25-31.
21. Yu H, Gibson JA, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol. 2007; 128: 776-782.